CROMOLYN SODIUM OPHTHALMIC SOLUTION USP, 4% Sterile

Manufacturer
Akorn | Akorn Operating Company LLC
Effective date
2022-01-25
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
5
Source
full-release
Hydrated at
2026-05-31 20:39:42

Label at a glance#

ProductCromolyn Sodium
Active ingredientCromolyn Sodium
Label structure12 sections

Indications and uses

Cromolyn Sodium Ophthalmic Solution is indicated in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.

Dosage and administration

The dose is 1 or 2 drops in each eye 4 to 6 times a day at regular intervals. One drop contains approximately 1.6 mg cromolyn sodium. Patients should be advised that the effect of Cromolyn Sodium Ophthalmic Solution therapy is dependent upon its administration at regular intervals, as directed. Symptomatic response to therapy (decreased itching, tearing, redness, and discharge) is usually evident within a few days...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

DESCRIPTION

DESCRIPTION SECTION

Cromolyn Sodium Ophthalmic Solution USP, 4% is a clear, colorless, sterile solution intended for topical ophthalmic use.

Cromolyn Sodium is represented by the following structural formula:

Structural Formula
Structural Formula

Chemical Name: disodium 5-5' - [(2-hydroxytrimethylene)dioxy] bis [4-oxo-4H-1-benzopyran-2-carboxylate].

Pharmacologic Category: Mast cell stabilizer.

Each mL contains: Active: Cromolyn sodium 40 mg (4%); Inactives: Edetate disodium 0.1% and Water for Injection. It has a pH of 4.0 to 7.0; Preservative: Benzalkonium chloride 0.01%.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

In vitro and in vivo animal studies have shown that cromolyn sodium inhibits the degranulation of sensitized mast cells which occurs after exposure to specific antigens. Cromolyn sodium acts by inhibiting the release of histamine and SRS-A (slow-reacting substance of anaphylaxis) from the mast cell.

Another activity demonstrated in vitro is the capacity of cromolyn sodium to inhibit the degranulation of non-sensitized rat mast cells by phospholipase A and the subsequent release of chemical mediators. Another study showed that cromolyn sodium did not inhibit the enzymatic activity of released phospholipase A on its specific substrate.

Cromolyn sodium has no intrinsic vasoconstrictor, antihistamine, or anti-inflammatory activity.

Cromolyn sodium is poorly absorbed. When multiple doses of cromolyn sodium ophthalmic solution are instilled into normal rabbit eyes, less than 0.07% of the administered dose of cromolyn sodium is absorbed into the systemic circulation (presumably by way of the eye, nasal passages: buccal cavity and gastrointestinal tract). Trace amounts (less than 0.01%) of the cromolyn sodium dose penetrate into the aqueous humor and clearance from this chamber is virtually complete within 24 hours after treatment is stopped.

In normal volunteers, analysis of drug excretion indicates that approximately 0.03% of cromolyn sodium is absorbed following administration to the eye.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Cromolyn Sodium Ophthalmic Solution is indicated in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Cromolyn Sodium Ophthalmic Solution is contraindicated in those patients who have shown hypersensitivity to cromolyn sodium or to any of the other ingredients.

PRECAUTIONS

PRECAUTIONS SECTION

GENERAL PRECAUTIONS SECTION

General: Patients may experience a transient stinging or burning sensation following application of Cromolyn Sodium Ophthalmic Solution.

The recommended frequency of administration should not be exceeded (see DOSAGE AND ADMINISTRATION).

INFORMATION FOR PATIENTS SECTION

Information for Patients: Patients should be advised to follow the patient instructions listed on the Information for Patient's sheet.

Users of contact lenses should refrain from wearing lenses while exhibiting the signs and symptoms of vernal keratoconjunctivitis, vernal conjunctivitis, or vernal keratitis. Do not wear contact lenses during treatment with Cromolyn Sodium Ophthalmic Solution.

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Carcinogenesis, Mutagenesis, and Impairment of Fertility: Long term studies of Cromolyn Sodium in mice (12 months intraperitoneal administration at doses up to 150 mg/kg three days per week): hamsters (intraperitoneal administration at doses up to 52.6 mg/kg three days per week for 15 weeks followed by 17.5 mg/kg three days per week for 37 weeks), and rats (18 months subcutaneous administration at doses up to 75 mg/kg six days per week) showed no neoplastic effects. The average daily maximum dose levels administered in these studies were 192.9 mg/m2 for mice, 47.2 mg/m2 for hamsters and 385.8 mg/m2 for rats. These doses correspond to approximately 6.8,1.7, and 14 times the maximum daily human dose of 28 mg/m2.

Cromolyn Sodium showed no mutagenic potential in the Ames Salmonella/microsome plate assays, mitotic gene conversion in Saccharomyces cerevisiae and in an In vitro cytogenetic study in human peripheral lymphocytes.

No evidence of impaired fertility was shown in laboratory reproduction studies conducted subcutaneously in rats at the highest doses tested, 175 mg/kg/day (1050 mg/m2) in males and 100 mg/kg/day (600 mg/m2) in females. These doses are approximately 37 and 21 times the maximum daily human dose, respectively, based on mg/m2.

Pregnancy

PREGNANCY SECTION

TERATOGENIC EFFECTS SECTION

Teratogenic Effects: Pregnancy Category B. Reproduction studies with cromolyn sodium administered subcutaneously to pregnant mice and rats at maximum daily doses of 540 mg/kg (1620 mg/m2) and 164 mg/kg (984 mg/m2), respectively, and intravenously to rabbits at a maximum daily dose of 485 mg/kg (5820 mg/m2) produced no evidence of fetal malformation. These doses represent approximately 57, 35, and 205 times the maximum daily human dose, respectively, on a mg/m2 basis. Adverse fetal effects (increased resorption and decreased fetal weight) were noted only at the very high parenteral doses that produced maternal toxicity. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

NURSING MOTHERS SECTION

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Cromolyn Sodium Ophthalmic Solution is administered to a nursing woman.

PEDIATRIC USE SECTION

Pediatric Use: Safety and effectiveness in children below the age of 4 years have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The most frequently reported adverse reaction attributed to the use of cromolyn sodium, on the basis of reoccurrence following readministration, is transient ocular stinging or burning upon instillation.

The following adverse reactions have been reported as infrequent events. It is unclear whether they are attributed to the drug:

Conjunctival injection; watery eyes; itchy eyes; dryness around the eye; puffy eyes; eye irritation; and styes.

Immediate hypersensitivity reactions have been reported rarely and include dyspnea, edema, and rash.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The dose is 1 or 2 drops in each eye 4 to 6 times a day at regular intervals. One drop contains approximately 1.6 mg cromolyn sodium.

Patients should be advised that the effect of Cromolyn Sodium Ophthalmic Solution therapy is dependent upon its administration at regular intervals, as directed.

Symptomatic response to therapy (decreased itching, tearing, redness, and discharge) is usually evident within a few days, but longer treatment for up to six weeks is sometimes required. Once symptomatic improvement has been established, therapy should be continued for as long as needed to sustain improvement.

If required, corticosteroids may be used concomitantly with Sodium Chloride Ophthalmic Solution.

HOW SUPPLIED

HOW SUPPLIED SECTION

Cromolyn Sodium Ophthalmic Solution USP 4% is supplied as 10 mL of solution in an opaque polyethylene bottle with a controlled dropper tip. NDC 17478-291-11

STORAGE AND HANDLING SECTION

Storage: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Protect from light-store in original carton.

Keep tightly closed.

Keep out of reach of children.

Akorn
Manufactured By:
AKORN, INC.
Lake Forest, IL 60045

CR00N                              Rev. 06/16

PHARMACIST – DETACH HERE AND GIVE INSTRUCTIONS TO PATIENTS

SPL PATIENT PACKAGE INSERT SECTION

Information for the Patient

Cromolyn Sodium Ophthalmic Solution USP, 4% Sterile

It is important to use Cromolyn Sodium Ophthalmic Solution regularly, as directed by your physician.

  1. Thoroughly wash your hands.
  2. Remove safety seal (Figure 1).Figure 1Figure 1
  3. Remove cap (Figure 2).Figure 2Figure 2
  4. Sit or stand comfortably, with your head tilted back (Figure 3).Figure 3Figure 3
  5. Open eyes, look up, and draw the lower lid of your eye down gently with your index finger (Figure 4).Figure 4Figure 4
  6. Hold the Cromolyn Sodium Ophthalmic Solution bottle upside down. Place dropper tip as close as possible to the lower eyelid and gently squeeze out the prescribed number of drops (Figure 5).Figure 5Figure 5
  7. Do not touch the eye or eyelid with the dropper tip.
  8. Blink a few times to make sure the eye is covered with the solution.
  9. Close your eye and remove any excess solution with a clean tissue.
  10. Repeat process in the other eye.

Special Tips:

  1. Avoid placing Cromolyn Sodium Ophthalmic Solution directly on the cornea (the area just over the pupil), because it is especially sensitive. You will find the administration of eye drops more comfortable if you place the drops just inside the lower eyelid as shown in Figure 5 on the previous page.
  2. To avoid contamination of the solution, do not touch dropper tip to the eye, fingers, or any other surface. Replace cap after use. It is recommended that any remaining contents be discarded after the treatment period prescribed by your physician.
  3. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light — store in original carton.
  4. Keep tightly closed and out of the reach of children.
  5. Do not use with any other ocular medication unless directed by your physician. Do not wear contact lenses during treatment with Cromolyn Sodium Ophthalmic Solution.

Akorn
Manufactured By:
AKORN, INC.
Lake Forest, IL 60045
Rev. 06/16

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Principal Display Panel Text for Container Label:

NDC 17478-291-11

Cromolyn

Sodium

Ophthalmic

Solution, USP

4%

Rx only Sterile 10 mL

FOR OPHTHALMIC USE ONLY

Principal Display Panel Text for Container Label
Principal Display Panel Text for Container Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Principal Display Panel Text for Carton Label:

NDC 17478-291-11

Cromolyn

Sodium

Ophthalmic

Solution, USP

4%

FOR OPHTHALMIC USE ONLY

Sterile

10 mL

Rx only Akorn Logo

Principal Display Panel Text for Carton Label
Principal Display Panel Text for Carton Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
831109cromolyn sodium 4 % Ophthalmic SolutionPSN5
831109cromolyn sodium 40 MG/ML Ophthalmic SolutionSCD5
831109cromolyn sodium 4 % Ophthalmic SolutionSY5

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
CROMOLYN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
d745b171-bd61-e8c6-cc94-d4add278788bProduct name320230113
a7fea5a7-679e-334b-faff-75e43fb3beb5Product name220171208

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
17478-291-112024-01-30C16284748780-11030e365-2b83-111a-e063-dadaa90a10e2CROMOLYN SODIUM OPHTHALMIC SOLUTION USP, 4% Sterile

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
17478-291-11Cromolyn Sodium1 in 1 CARTONSOLUTION/ DROPS15
17478-291-11Cromolyn Sodium10 mL in 1 BOTTLE, DROPPERSOLUTION/ DROPS105

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
17478-291CROMOLYN SODIUM SOLUTION/ DROPS [AKORN]5Legacy NDC, 2 package rows20220126_e604ed4d-d8a7-4f65-a386-b4bd6137d987.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
17478-291-11ML - Milliliter17478-2914402d7f0-5460-4224-a508-e4d16d39f46612012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
Cromolyn SodiumACTIVE INGREDIENTQ2WXR1I0PK2
CromolynACTIVE MOIETYY0TK0FS77W2
Benzalkonium ChlorideINACTIVE INGREDIENTF5UM2KM3W72
EDETATE DISODIUMINACTIVE INGREDIENT7FLD91C86K2
WATERINACTIVE INGREDIENT059QF0KO0R2

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 5 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
17478-29117478-291-11

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 4 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 2 · 101 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KGEL / VAGINAL5 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KINJECTION, SUSPENSION / INTRA-ARTICULAR1 mgExact identifier — unii candidate
77 equally ranked IID candidates
Benzalkonium ChlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION / TOPICAL0.02 %w/vExact identifier — unii candidate
24 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSPRAY / NASAL1 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KELIXIR / ORAL1.3 mg/5mlExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSUSPENSION / OPHTHALMIC0.06 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KGEL / TRANSDERMAL1 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSYSTEM / IONTOPHORESIS0.1 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KOINTMENT / TOPICAL1 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KGEL / TOPICAL24 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KLIQUID / INTRAVENOUS0.03 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KPOWDER, FOR SUSPENSION / ORAL285 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSOLUTION / RESPIRATORY (INHALATION)43 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KINJECTION / SUBCUTANEOUS6 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSUSPENSION, EXTENDED RELEASE / ORAL40 mgExact identifier — unii candidate
77 equally ranked IID candidates
Benzalkonium ChlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION / OPHTHALMIC2 %w/vExact identifier — unii candidate
24 equally ranked IID candidates
Benzalkonium ChlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SUSPENSION / AURICULAR (OTIC)0.01 %w/vExact identifier — unii candidate
24 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSPRAY / RESPIRATORY (INHALATION)0.05 %w/wExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSUSPENSION / RESPIRATORY (INHALATION)0.01 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KCAPSULE / ORAL5 mgExact identifier — unii candidate
77 equally ranked IID candidates
Benzalkonium ChlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION/ DROPS / AURICULAR (OTIC)0 %w/vExact identifier — unii candidate
24 equally ranked IID candidates
Benzalkonium ChlorideBENZALKONIUM CHLORIDEF5UM2KM3W7OINTMENT / TOPICAL0.03 %w/wExact identifier — unii candidate
24 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KENEMA / RECTAL60 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KINJECTION, EMULSION / INTRAVENOUS59 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KTABLET, FILM COATED / ORAL4 mgExact identifier — unii candidate
77 equally ranked IID candidates
Benzalkonium ChlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SUSPENSION/ DROPS / AURICULAR (OTIC)0.02 %w/vExact identifier — unii candidate
24 equally ranked IID candidates
Benzalkonium ChlorideBENZALKONIUM CHLORIDEF5UM2KM3W7CLOTH / TOPICALNAExact identifier — unii candidate
24 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSUSPENSION/ DROPS / AURICULAR (OTIC)0.01 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
Benzalkonium ChlorideBENZALKONIUM CHLORIDEF5UM2KM3W7GEL / OPHTHALMIC0.01 %w/wExact identifier — unii candidate
24 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KINJECTION, SOLUTION / INTRAMUSCULAR4 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KINJECTION / INTRAMUSCULAR10 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KEMULSION / OPHTHALMIC0.3 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KCREAM / VAGINAL3 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KEMULSION / TOPICAL0.11 %w/wExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KTABLET, DELAYED RELEASE / ORAL100 mgExact identifier — unii candidate
77 equally ranked IID candidates
Benzalkonium ChlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SPRAY / NASAL1 mgExact identifier — unii candidate
24 equally ranked IID candidates
Benzalkonium ChlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SUSPENSION/ DROPS / TOPICALNAExact identifier — unii candidate
24 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSOLUTION / NASAL100 mg/100mlExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSYSTEM / TOPICAL126 mgExact identifier — unii candidate
77 equally ranked IID candidates
Benzalkonium ChlorideBENZALKONIUM CHLORIDEF5UM2KM3W7LOTION / TOPICAL0.1 %w/wExact identifier — unii candidate
24 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSOLUTION / AURICULAR (OTIC)0.1 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KCREAM, AUGMENTED / TOPICAL2 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KTABLET, ORALLY DISINTEGRATING / ORAL3 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSOLUTION/ DROPS / OPHTHALMIC0.13 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KGEL / OPHTHALMIC396 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KINJECTION / INTRAVASCULAR0.48 mgExact identifier — unii candidate
77 equally ranked IID candidates
Benzalkonium ChlorideBENZALKONIUM CHLORIDEF5UM2KM3W7INJECTION / INTRALESIONAL1 mgExact identifier — unii candidate
24 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KCREAM / TOPICAL14 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KTABLET, COATED / ORAL0.21 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSYRUP / ORAL40 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KINJECTION, SOLUTION / INTRAVENOUS7 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSUSPENSION / ORAL30 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSOLUTION / RECTAL97 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KINJECTION / INTRALESIONAL0.05 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
Benzalkonium ChlorideBENZALKONIUM CHLORIDEF5UM2KM3W7INJECTION / INTRAMUSCULAR1 mgExact identifier — unii candidate
24 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KINJECTION / INTRAVENOUS10 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KTABLET / ORAL100 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KAEROSOL, FOAM / TOPICAL0.05 %w/wExact identifier — unii candidate
77 equally ranked IID candidates
Benzalkonium ChlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION / NASAL40.46 mg/100mlExact identifier — unii candidate
24 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KINJECTION, SUSPENSION / SOFT TISSUE1 mgExact identifier — unii candidate
77 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A074706-001CROMOLYN SODIUMCROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-2984e616aacf4f…
2026-08-18 06:07:402026-07A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-2931067a03dcf5…
2025-08-23 18:47 UTC2025-08A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-296a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-2903ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-292680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-295bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-2979d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-291e350fbaab3a…
2024-05-31 18:47 UTC2024-05A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-298072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-295c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-295d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-294b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-2974a2ff9319b5…
2022-03-09 01:35 UTC2022-03A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-29bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-29782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-2987673890dc5c…
2021-03-12 10:30 UTC2021-03A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-295aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-298869cabd3fbd…
2020-11-12 02:37 UTC2020-11A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-29c0c555d07b60…
2019-12-14 00:12 UTC2019-12A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-293f01610625f2…
2019-09-15 20:21 UTC2019-09A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-29b00525d2431f…
2019-07-19 19:46 UTC2019-07A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-29ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-296a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-291c564ffb4f44…
2023-12-20 04:57 UTC2023-12A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-299b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-293f0d92c62455…
2023-05-13 08:27 UTC2023-05A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMIC1998-04-29053a50430f4f…
2023-01-26 05:58 UTC2023-01A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-293bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-293a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A074706-001CROMOLYN SODIUM4%SOLUTION/DROPS / OPHTHALMICATRS1998-04-29f41ea6bd6efb…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A074706-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A074706-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A074706-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A074706-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A074706-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A074706-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A074706-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A074706-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A074706-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A074706-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A074706-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A074706-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A074706-001AT1ea99ee380514…
2023-01-26 05:58 UTC2023-01A074706-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A074706-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A074706-001AT1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A074706-001AT1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A074706-001AT1cb3db0bc1861…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
2c91e02d-0a38-4225-b30d-249fd182568fe604ed4d-d8a7-4f65-a386-b4bd6137d9872022-01-25Adverse reactionsExact identifier
spl id: 2c91e02d-0a38-4225-b30d-249fd182568f
spl set id: e604ed4d-d8a7-4f65-a386-b4bd6137d987

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.